Madison-based Cellectar Biosciences Inc. reported a net loss of about $8.1 million ($1.77/share) for all of 2014. That compares with a net loss of $10.8 million ($3.86/share) for all of 2013. Operating expenses fell from $12.4 million in 2013 to $9.9 million in 2014.
Cellectar develops agents for the detection and treatment of cancer.
